9 news items
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FGEN
3 Jun 24
Tregs via antibody dependent cellular cytotoxicity (ADCC) in the tumor microenvironment and enhance anti-tumor T cell responses, leading to enhanced
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FGEN
3 Jun 24
and explore the potential of FG-3165 in enhancing anti-tumor immune responses in the tumor microenvironment." The FDA IND clearance
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
that the combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab yielded tumor response rates nearly triple historical results. Should
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
that the combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab yielded tumor response rates nearly triple historical results. Should
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN
23 May 24
of the trial and further explore the potential of 89Zr-DFO-YS5 as a predictive biomarker of response." The poster
rmurr6dyq6r9d5ucesn5 1d41nseaj8bmvu6lghp34gsmraz8b
FGEN
6 May 24
evaluable patients, 20% met the criteria of a partial response, or measurable tumor reduction in size of ≥ 30%, with a median duration of response
gaxg7p
ABBV
FGEN
3 Apr 24
evaluable patients.
20% met the criteria of a partial response, or tumor reduction in size of over 30%, with a median duration of response
a0llv9j7lnbcryogjjsiwkezmg7wg3hbvo1thgg3i97smyu 0g
FGEN
2 Apr 24
patients, 20% met the criteria of a partial response, or tumor reduction in size of ≥ 30%, with a median duration of response of 7.5
47ncoe0slg5b2vmprgpakr4oms0y7
FGEN
2 Apr 24
PSA50 response in 36% of patients
- Prev
- 1
- Next